

Medical Device Sector Surveillance & Biometrics Executive Department قطاع الأجهزة والمنتجات الطبية الإدارة التنفيذية للرقابة والقياسات الحيوية

## **Safety Communication**

رسالة سلامة

## Risk of a false positive result when using the Reagents for the BD MAX<sup>TM</sup> System.

Device/ Product Description:	SARS-CoV-2 Reagents		
Brand:	BD MAX <sup>™</sup> System		
Affected product:	REFs: 445003 and 445003-01		
Manufacturer:	Becton Dickinson (BD)		
Problem:	The manufacturer has identified a potential for false positive results when using the Reagents for the BD MAX <sup>TM</sup> System. A false positive SARS-CoV-2 test result could lead to a delay in diagnosis and potentially cause the patient to be exposed to COVID-19 if they are isolated with an infected individual.		
Recommendation /Actions:	<ul> <li>Recommendations for Health Care Providers and Facility Staff:</li> <li>Make sure that this document, with accompanying FSNs, are reached to the end-users.</li> <li>The user Defined Protocol (UDP) threshold for the N2 target in the IFU needs to be revised from 50 RFU to 80 RFU.</li> <li>Consider any positive result presumptive from tests using the BD SARS-CoV-2 Reagents for the BD Max System. Consider confirming with an alternate authorized test.</li> <li>For more information, Please click here.</li> <li>If you think you had a problem with your device or a device your patient uses, please do not hesitate to report the problem to SFDA through: NCMDR Vigilance system</li> </ul>		

	19999 unified call center		
Devices/Products photo:			
Authorized Bonnegontative	AR name:	Becton Dickinson B.V.	
Representative Details	Assigned Contact Person:	Saleh Al sohibanei	
	Mobile/Phone:	0544760333	
	Email:	Saleh.AL.SOHIBANEI@bd.com	

